A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkad360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Maria-Ioanna Beredaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Candida parapsilosis, Antifungal Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas.
Abstract (Originalsprache)
Background
Pharmacokinetic/pharmacodynamic (PK/PD) targets of echinocandins failed to support current clinical breakpoints of Candida parapsilosis as the PTA is low for susceptible isolates despite the good clinical efficacy of echinocandins against these infections. We therefore investigated the effect of micafungin against C. parapsilosis using an in vitro PK/PD in the presence of 10% human serum.
Methods
Three susceptible (MIC = 0.5–2 mg/L) and one resistant (MIC > 8 mg/L) C. parapsilosis sensu stricto isolates were tested at two different inocula (104 and 103 cfu/mL) simulating micafungin human exposures in RPMI and in RPMI + 10% pooled human serum. The exposure–effect relationship tAUC0–24/MIC was described and different PK/PD targets were determined in order to calculate the PTA for the standard 100 mg IV q24h dose.
Results
A maximal effect was found at fCmax ≥ 4 mg/L in RPMI and tCmax ≥ 64 mg/L (fCmax = 0.08 mg/L) in the presence of serum for which in vitro PK/PD targets were 50 times lower. Stasis in the presence of serum was found at 272–240 tAUC0–24/MIC, close to the clinical PK/PD target (285 tAUC/MIC), validating the in vitro model. However, the PTA was low for susceptible isolates with EUCAST/CLSI MICs ≤ 2 mg/L. Among the different PK/PD targets investigated, the PK/PD target 28 tAUC/MIC associated with 10% of maximal effect with the low inoculum resulted in PTAs ≥ 95% for susceptible isolates with EUCAST/CLSI MICs ≤ 2 mg/L.
Conclusions
A new PK/PD target was found for micafungin and C. parapsilosis that supports the current clinical breakpoint. This target could be used for assessing echinocandin efficacy against C. parapsilosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Joseph Meletiadis
Förderung
- Astellas
Zitieren
APA
Beredaki, M. I., Pournaras, S., & Meletiadis, J. (2024). A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad360
Vancouver
Beredaki MI, Pournaras S, Meletiadis J. A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkad360
BibTeX
@article{Beredaki2024,
author = {Beredaki, Maria-Ioanna and Pournaras, Spyros and Meletiadis, Joseph},
title = {A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkad360}
}
EUVIMED